Pathogenesis and Novel Therapeutics in Asthma
Asthma is a prevalent chronic inflammatory disease of the airways with complex etiology and mechanistic pathways and variable clinical presentation. Such heterogeneity renders the search for targeted therapies difficult. Currently, the best-known disease phenotype with tailored biological treatment...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_101322 | ||
005 | 20230714 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230714s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-7843-9 | ||
020 | |a 9783036578422 | ||
020 | |a 9783036578439 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-7843-9 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
100 | 1 | |a Bazan-Socha, Stanislawa |4 edt | |
700 | 1 | |a Bazan-Socha, Stanislawa |4 oth | |
245 | 1 | 0 | |a Pathogenesis and Novel Therapeutics in Asthma |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (168 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Asthma is a prevalent chronic inflammatory disease of the airways with complex etiology and mechanistic pathways and variable clinical presentation. Such heterogeneity renders the search for targeted therapies difficult. Currently, the best-known disease phenotype with tailored biological treatment is eosinophilic asthma; however, even in some of these patients, anti-IL5 treatment is ineffective. Furthermore, about a quarter of patients, especially those with a severe phenotype, develop progressive and irreversible airway obstruction, leading to persistent symptoms despite optimized treatment. Therefore, new therapeutic approaches are still needed, particularly in severe asthma. The Special Issue presents asthma research focusing on modern personalized therapeutic approaches. Particular interest is directed to novel asthma biomarkers, including molecular and epigenetic ones, shining new light on pathogenesis, phenotyping, and customized therapy in various airway inflammatory patterns of the disease. In addition, research articles on airway epithelial cell dysfunction, airway remodeling, and the overlap between asthma and chronic obstructive pulmonary disease are welcomed. Stanislawa Bazan-Socha (Guest Editors) | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a bronchial epithelial cells | ||
653 | |a extracellular vesicles | ||
653 | |a miRNAs | ||
653 | |a airway epithelium | ||
653 | |a asthma | ||
653 | |a cellular compartmentalization | ||
653 | |a allergic rhinitis | ||
653 | |a allergen immunotherapy | ||
653 | |a bronchial asthma | ||
653 | |a component-resolved diagnosis | ||
653 | |a sublingual immunotherapy | ||
653 | |a fungal sensitization | ||
653 | |a IL-17A | ||
653 | |a Candida albicans | ||
653 | |a mediation effect | ||
653 | |a oxidative stress | ||
653 | |a CBA assay | ||
653 | |a airway remodeling | ||
653 | |a severe asthma | ||
653 | |a bronchial fibroblasts | ||
653 | |a fibrosis | ||
653 | |a Bcl10 | ||
653 | |a NF-κB pathway | ||
653 | |a cytokines | ||
653 | |a efficacy | ||
653 | |a investigational | ||
653 | |a Phase I | ||
653 | |a Phase II | ||
653 | |a RCT | ||
653 | |a allergy | ||
653 | |a eosinophils | ||
653 | |a immune health | ||
653 | |a natural therapeutics | ||
653 | |a prostacyclin | ||
653 | |a allergic inflammation | ||
653 | |a proinflammatory | ||
653 | |a anti-inflammatory | ||
653 | |a BLT2 | ||
653 | |a G-CSF | ||
653 | |a 12-LO | ||
653 | |a neutrophil | ||
653 | |a airway inflammation | ||
653 | |a n/a | ||
653 | |a miRNA | ||
653 | |a children | ||
653 | |a serum | ||
653 | |a exhaled breath condensate | ||
653 | |a diagnosis | ||
653 | |a exacerbation | ||
653 | |a biomarkers | ||
653 | |a factors | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7416 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/101322 |7 0 |z DOAB: description of the publication |